#dr-reddys
Dr Reddy’s launches oral semaglutide in India
Dr Reddys Laboratories has launched its oral semaglutide biosimilar for type 2 diabetes in India. The drug, Obeda, is available in three tablet strengths for daily use. This launch expands access to advanced diabetes care. Dr Reddys is the second Indian compa…
Dr Reddy’s launches oral semaglutide biosimilar Obeda
Dr. Reddy’s launches Obeda, an affordable oral semaglutide biosimilar for type 2 diabetes, enhancing treatment options in India.
BREAKINGDr Reddy's launches oral semaglutide biosimilar Obeda in India
Dr. Reddy's Laboratories proudly presents Obeda, a groundbreaking oral semaglutide biosimilar for managing Type 2 diabetes in India. This innovative treatment offers patients the ease of a once-daily oral dosage, available in various strengths to effectively …
Stocks in news: Airtel, Tata Motors, Dr Reddy's, NTPC, Dixon Technologies
Markets faced selling pressure on Tuesday due to weak global cues and macroeconomic concerns, with the Nifty approaching support at 23,150. Several companies like Airtel, Tata Motors, and Dr Reddy's are in focus due to earnings reports and other news developm…
Dr. Reddy’s to Launch Generic Ozempic in Canada Within Days
Dr Reddy’s Laboratories Ltd. plans to launch its version of generic Ozempic this month, filling a void in the Canadian market months after a key patent expiry and paving the way for cheaper access to the GLP-1 drugs.
Dr. Reddy's to launch generic Ozempic in Canada within days
Dr Reddy’s Laboratories Ltd. plans to launch its version of generic Ozempic this month, filling a void in the Canadian market. Read here